# Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer

> **NCT07379918** · — · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 1000 (estimated)

## Conditions studied

- Breast Cancer (Early Breast Cancer)
- Breast Cancer Survivors
- Breast Cancer Prognostic
- Early Hormone Receptor-positive (HR-positive)
- HER2-negative Breast Cancer

## Interventions

- **OTHER:** Endopredict test

## Key facts

- **NCT ID:** NCT07379918
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-28
- **Primary completion:** 2031-06-28
- **Final completion:** 2031-06-28
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07379918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07379918, "Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07379918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*